Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02056626 · ClinicalTrials.gov registry record · Phase 4

Conditioned Pharmacotherapeutic Effects in Hypertension

A Phase 4 study of Hypertension, sponsored by University of Rochester.

Completed
Registry status
Phase 4
Development phase
44
Enrollment target
1
Study location

NCT02056626: Completed Phase 4 study of Hypertension, sponsored by University of Rochester.

NCT02056626 is a Phase 4 study of Hypertension that has completed, run by University of Rochester. The registered enrollment target is 44 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02056626, a Phase 4 study of Hypertension, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Phase 4
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

The proposed research is designed to determine if the application of classical conditioning operations could influence the clinical effects of a regimen of antihypertensive drug therapy. It will be determined if, capitalizing on conditioned pharmacotherapeutic effects, patients can be effectively treated with smaller cumulative amounts of drug.

Conditions Studied

Interventions

  • DRUG carvedilol

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2011-03
Est. Completion 2018-12-31
Phase Phase 4
University of Rochester

636 total trials

What the finished NCT02056626 record still lists

NCT02056626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which carvedilol is the first listed.

NCT02056626 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02056626 about?

NCT02056626 is a clinical study titled "Conditioned Pharmacotherapeutic Effects in Hypertension". The proposed research is designed to determine if the application of classical conditioning operations could influence the clinical effects of a regimen of antihypertensive drug therapy. It will be determined if, capitalizing on conditioned pharmacotherapeutic effects, patients can be effectively tr...

What is the current status of trial NCT02056626?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2011-03. Estimated completion is 2018-12-31.

What conditions does trial NCT02056626 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT02056626?

The interventions under investigation include: carvedilol (DRUG).

Who is sponsoring clinical trial NCT02056626?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02056626 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02056626's enrollment target sits among peer trials

44 381st of 470 higher than 88 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02056626, the US trial registry maintained by the National Library of Medicine. NCT02056626 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.